Davol Inc., a subsidiary of C.R. Bard, Inc. offers a non-crosslinked xenograft device for use in soft tissue repair including hernia and abdominal wall reconstruction. Features include:

• A proprietary technology that maintains an acellular structurally intact, non crosslinked porcine dermal matrix for enhanced biocompatibility in host tissue.
• A dermal matrix that supports revascularization, remodeling and regeneration for abdominal wall and hernia repairs.
• Recently published data in the American Journal of Surgery from the Brigham and Women's Hospital studied the use of XenMatrix in complex abdominal wall defects and reported a 93 percent success rate with over 16 months follow-up.

For more information, visit www.davol.com